The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to OraSure Technologies, Inc. for the procurement of 10,000 OraSure OraQuick ® Ebola Rapid Antigen Tests for the rapid detection of Ebola in three Ebola affected countries in West Africa. OraSure Technologies has received Emergency Use Authorization (EUA) from the FDA for their OraQuick® Ebola Rapid Antigen Test. OraSure is the only company that has the EUA approved device for both whole blood and cadaver samples that have been previously evaluated at the CDC and in West Africa. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-2 (b)(1)(i) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals.

This notice of intent is not a request for competitive quotations; however, all quotations/responses received within five(5) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to Leonard (Mac) Mutter at [email protected] by 5:00pm Eastern, 08/05/2016

Bid Protests Not Available